Profitability
33.0%Premium research · Exosens · August 2026 · EN
Exceptional technology.
A price that demands patience.
A rare European defence technology asset with structural growth and exceptional margins — but a valuation that leaves little room for error.
MITUXA VERDICT
WATCHMITUXA Quality Score 85 / 100Reference price€63.55
Fair value€59–62
Attractive zone€50–55
High conviction≤ €48
BEYOND THE OBVIOUS
The moat is an ecosystem,
not simply a product.
Exosens does not manufacture the most visible defence platforms. It builds some of the critical technologies that allow them to detect, identify and operate when others cannot see.
Its advantage rests on several layers: accumulated know-how, mission-critical component qualification, long customer relationships, industrial capacity and ITAR-free sovereignty. Replicating the product is not enough; a competitor would need to reproduce the system around it.
The second engine, Detection & Imaging, gradually broadens the thesis into drones, counter-drone systems, nuclear applications, semiconductors and scientific instrumentation.
THE INVESTMENT CASE
Three numbers that define the quality
Second engine
+14.6%D&I organic growth
Detection & Imaging is becoming large enough to reshape the group's profile over time.Financial strength
1.2×net financial leverage
The balance sheet leaves room for capacity, R&D and targeted acquisitions — provided ROCE remains resilient.VALUATION
An excellent business.
Very different returns at different prices.
At €63.55, our 2030 base case implies approximately €88 per share, or close to an 8% annualised return excluding dividends. That does not yet provide enough room for error. The €50–55 range becomes attractive; at €48 or below, Exosens can become a high-conviction candidate if the thesis remains intact.
WHAT COULD BREAK THE THESIS
- Amplification organic growth remains below 5% for an extended period.
- New capacity runs ahead of orders and creates structural overcapacity.
- The technology gap narrows, weakening qualifications or margins.
- Acquisitions replace organic growth while ROCE falls and leverage rises.
- Expectations embedded in the share price rise faster than execution.
COMPLETE RESEARCH · EN
Read the full
MITUXA report.
The complete 25-page report examines the business model, value chain, moat, 5G technology, industrial scarcity, Detection & Imaging, drones, financial quality, ROCE, competition, three valuation scenarios and the conditions that would invalidate the thesis.
Open the full PDF in English ↗Free and open to everyone. For informational and educational purposes only.THE MITUXA COMMUNITY
Research is open.
The community is the value.
All MITUXA research is open to everyone through 31 December 2026. Subscribe to follow every investment thesis, result and decision — and to join a community of investors who want to look Beyond the Obvious.
Continue free ↗